SAN DIEGO, CA, February 16, 2017 – As 2016 was coming to a close, two leading fundamental research journals,
Molecular Pharmaceutics and
Current Alzheimer Research, independently published studies of two novel selective 5-HT6R serotonin receptor antagonists for Alzheimer’s Disease treatment, AVN-211 and AVN-322, that have shown to improve cognition and learning, demonstrating high therapeutic potential. According to the studies, both compounds have been confirmed to have high efficacy, improved selectivity and low toxicity compared to other available drugs and drug candidates.
The innovative compounds have been developed within the framework of ChemDiv’s multi-year collaboration with Avineuro Pharmaceuticals, where ChemDiv was contributing the expertise in drug discovery and development and utilizing its innovative multi-disciplinary research platform to help advance Avineuro's programs.
The
in vivo studies highlighted in the publications demonstrated good safety profiles and favorable pharmacokinetics of the two compounds. While AVN-211 was shown to be capable of significantly delaying or even disrupting the progress of the memory function decline associated with Alzheimer’s disease, AVN-322 was proven to enhance cognition by considerably restoring scopolamine- and MK-801-induced cognitive dysfunction. Both lead candidates have shown excellent oral bioavailability, increased blood-barrier (BBB) penetration and improved selectivity to 5-HT6R compared to the reference drugs, making them highly potent drug candidates for treatment of neurodegenerative and psychiatric disorders.
Alzheimer’s disease is a debilitating ailment that causes severe memory loss and disruption of cognitive processes leading to disability and death. In the US the costs of battling the disease exceed the financial burden associated with cancer and cardiovascular diseases. Active research is being conducted to develop treatments for this life-threatening condition, and, currently, 5-HT6R is regarded as one of the most potent biological targets for Alzheimer’s disease.
About ChemDivChemDiv is a recognized global leader in discovery chemistry with one of the industry’s largest, most diverse, and most productive collections of over 1,600,000 individually-crafted, lead-like, drug-like small molecules. Over the past 25 years the ChemDiv team has delivered hundreds of leads, drug candidates and new drug approvals in the areas of CNS, oncology, virology, inflammation, cardio and metabolic diseases to its pharma and biotech customers around the globe. ChemDiv’s integrated drug discovery and evaluation platforms allow for an accelerated, cost-effective R&D process aimed at rapidly bringing a project from target ID to Phase 3 clinical candidate and beyond.
http://www.chemdiv.com/About AvineuroAvineuro Pharmaceuticals discovers and develops novel small molecules for unmet medical needs in neurology and psychiatry. Founded in August 2008 and headquartered in San Diego, California, Avineuro emphasizes a rational approach that combines modern medicinal chemistry with streamlined pre-clinical and clinical development studies, thus, allowing for a fast transition from a proof-of-concept to a product candidate stage. Currently the company is focused on developing top selective and multi-target serotonin 5-HT6 receptor antagonists to treat the cognitive disorders such as Alzheimer’s disease, Huntington’s disease, Schizophrenia, Down’s syndrome, and other CNS diseases associated with cognitive dysfunctions. Learn more http://www.avineuro.com/
